Skip to main content

Advertisement

Log in

Reply to Comments on: “Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp cooling system in early breast cancer patients treated with anthracyclines.”

  • Correspondence
  • Published:
British Journal of Cancer Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Rugo, H. S., Klein, P., Melin, S. A., Hurvitz, S. A., Melisko, M. E., Moore, A. et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA 317, 606–614 (2017).

    Article  Google Scholar 

  2. Rugo, H. S., Serrurier, K. M., Melisko, A., Glencer, A., Hwang, J., D’Agostino, R. et al. Use of the DigniCapTM system to prevent hair loss in women receiving chemotherapy (CTX) for stage I breast cancer (BC). Cancer Res. 72(24 supp.), P2-12-11 (2012).

  3. Munzone, E., Bagnardi, V., Campennì, G., Mazzocco, K., Pagan, E., Tramacere, A. et al. Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp-cooling system in early breast cancer patients treated with anthracyclines. Br. J. Cancer https://doi.org/10.1038/s41416-019-0520-8 (2019).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

E.M., E.P., V.B., K.M. made substantial contribution to study design and were all involved in drafting the manuscript. All authors approved the final manuscript.

Corresponding author

Correspondence to Elisabetta Munzone.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

The original study was approved by the local ethic committee (Istituto Europeo di Oncologia, IRCCS). All patients signed written informed consent. The study was performed in accordance with the Declaration of Helsinki.

Funding

None.

Data availability

Data supporting the results reported in the article are available at Clinical Trial Office, European Institute of Oncology, Milan, Italy. Restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of European Institute of Oncology, Milan, Italy.

Additional information

Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Munzone, E., Pagan, E., Bagnardi, V. et al. Reply to Comments on: “Preventing chemotherapy-induced alopecia: a prospective clinical trial on the efficacy and safety of a scalp cooling system in early breast cancer patients treated with anthracyclines.”. Br J Cancer 121, 806 (2019). https://doi.org/10.1038/s41416-019-0577-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-019-0577-4

  • Springer Nature Limited

This article is cited by

Navigation